CARD 14 Polyclonal Antibody BT-AP01168
Specifications
| 20ul / 50ul / 100ul |
Background:
CARD14 (caspase recruitment domain family member 14) encodes a caspase recruitment domain-containing protein that is a member of the membrane-associated guanylate kinase (MAGUK) family of proteins. Members of this protein family are scaffold proteins that are involved in a diverse array of cellular processes including cellular adhesion, signal transduction and cell polarity control. This protein has been shown to specifically interact with BCL10, a protein known to function as a positive regulator of cell apoptosis and NF-kappaB activation. Alternate splicing results in multiple transcript variants.
Classification:
Primary antibody
Alternative names:
CARD14; CARMA2; Caspase recruitment domain-containing protein 14; CARD-containing MAGUK protein 2; Carma 2
Species reactivity:
Human;Mouse
Host:
Rabbit
Isotype:
IgG
Immunogen:
The antiserum was produced against synthesized peptide derived from human CAR14. AA range:291-340
Concentration:
1 mg/ml
Molecular weight:
113300
Applications:
IHC-p, IF, ELISA
Storage:
-20°C for one year
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.